(-)-epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice

Kimberly A. Grove, Sudathip Sae-Tan, Mary J. Kennett, Joshua D. Lambert

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Tea (Camellia sinensis, Theaceae) has been shown to have obesity preventive effects in laboratory studies. We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL). Following treatment with 0.32% EGCG for 6 weeks, a 44% decrease in body weight (BW) gain in high fat-fed, obese mice (P < 0.01) was observed compared to controls. EGCG treatment increased fecal lipid content by 29.4% (P < 0.05) compared to high fat-fed control, whereas in vitro, EGCG dose-dependently inhibited PL (IC 50 = 7.5mol/l) in a noncompetitive manner with respect to substrate concentration. (-)-Epicatechin-3-gallate exhibited similar inhibitory activity, whereas the nonester-containing (-)-epigallocatechin did not. In conclusion, EGCG supplementation reduced final BW and BW gain in obese mice, and some of these effects may be due to inhibition of PL by EGCG.

Original languageEnglish (US)
Pages (from-to)2311-2313
Number of pages3
JournalObesity
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Obese Mice
Lipase
Weight Gain
Fats
Body Weight
Theaceae
Camellia sinensis
epigallocatechin gallate
Obesity
Lipids
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

Grove, Kimberly A. ; Sae-Tan, Sudathip ; Kennett, Mary J. ; Lambert, Joshua D. / (-)-epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. In: Obesity. 2012 ; Vol. 20, No. 11. pp. 2311-2313.
@article{b876736ef42f43faa17eb6eff0771361,
title = "(-)-epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice",
abstract = "Tea (Camellia sinensis, Theaceae) has been shown to have obesity preventive effects in laboratory studies. We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL). Following treatment with 0.32{\%} EGCG for 6 weeks, a 44{\%} decrease in body weight (BW) gain in high fat-fed, obese mice (P < 0.01) was observed compared to controls. EGCG treatment increased fecal lipid content by 29.4{\%} (P < 0.05) compared to high fat-fed control, whereas in vitro, EGCG dose-dependently inhibited PL (IC 50 = 7.5mol/l) in a noncompetitive manner with respect to substrate concentration. (-)-Epicatechin-3-gallate exhibited similar inhibitory activity, whereas the nonester-containing (-)-epigallocatechin did not. In conclusion, EGCG supplementation reduced final BW and BW gain in obese mice, and some of these effects may be due to inhibition of PL by EGCG.",
author = "Grove, {Kimberly A.} and Sudathip Sae-Tan and Kennett, {Mary J.} and Lambert, {Joshua D.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1038/oby.2011.139",
language = "English (US)",
volume = "20",
pages = "2311--2313",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "11",

}

(-)-epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. / Grove, Kimberly A.; Sae-Tan, Sudathip; Kennett, Mary J.; Lambert, Joshua D.

In: Obesity, Vol. 20, No. 11, 01.11.2012, p. 2311-2313.

Research output: Contribution to journalArticle

TY - JOUR

T1 - (-)-epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice

AU - Grove, Kimberly A.

AU - Sae-Tan, Sudathip

AU - Kennett, Mary J.

AU - Lambert, Joshua D.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Tea (Camellia sinensis, Theaceae) has been shown to have obesity preventive effects in laboratory studies. We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL). Following treatment with 0.32% EGCG for 6 weeks, a 44% decrease in body weight (BW) gain in high fat-fed, obese mice (P < 0.01) was observed compared to controls. EGCG treatment increased fecal lipid content by 29.4% (P < 0.05) compared to high fat-fed control, whereas in vitro, EGCG dose-dependently inhibited PL (IC 50 = 7.5mol/l) in a noncompetitive manner with respect to substrate concentration. (-)-Epicatechin-3-gallate exhibited similar inhibitory activity, whereas the nonester-containing (-)-epigallocatechin did not. In conclusion, EGCG supplementation reduced final BW and BW gain in obese mice, and some of these effects may be due to inhibition of PL by EGCG.

AB - Tea (Camellia sinensis, Theaceae) has been shown to have obesity preventive effects in laboratory studies. We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL). Following treatment with 0.32% EGCG for 6 weeks, a 44% decrease in body weight (BW) gain in high fat-fed, obese mice (P < 0.01) was observed compared to controls. EGCG treatment increased fecal lipid content by 29.4% (P < 0.05) compared to high fat-fed control, whereas in vitro, EGCG dose-dependently inhibited PL (IC 50 = 7.5mol/l) in a noncompetitive manner with respect to substrate concentration. (-)-Epicatechin-3-gallate exhibited similar inhibitory activity, whereas the nonester-containing (-)-epigallocatechin did not. In conclusion, EGCG supplementation reduced final BW and BW gain in obese mice, and some of these effects may be due to inhibition of PL by EGCG.

UR - http://www.scopus.com/inward/record.url?scp=84868204577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868204577&partnerID=8YFLogxK

U2 - 10.1038/oby.2011.139

DO - 10.1038/oby.2011.139

M3 - Article

C2 - 21633405

AN - SCOPUS:84868204577

VL - 20

SP - 2311

EP - 2313

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 11

ER -